Can Molecular Analysis be Tapped to Tackle Brain Cancer?

Compared to treatment advances for other types of cancer, progress in treating brain cancer has been frustratingly slow. Still, understanding the molecular changes that drive brain cancer remains “potentially transformative,” says Paul Mischel, a cancer biologist and neuropathologist at the Ludwig Institute for Cancer Research in San Diego.

Read More

Fostering New Advances in Lung Cancer Research

A diverse group of about 220 physicians, patient advocates, and scientists in basic, translational, and clinical lung cancer research will convene in San Diego for an international conference organized by the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC). The focus of the conference is “Lung Cancer Translational Science from the Bench to the Clinic.”

Read More

Biosimilars: Breaking Through to Cancer Treatment

A little-talked-about provision of the 2010 Patient Protection and Affordable Care Act designed to improve access to innovative medical therapies has recently borne fruit for the cancer community in the form of two new therapeutic options for a wide range of cancers—bevacizumab-awwb (Mvasi) and trastuzumab-dkst (Ogivri).

Read More

How Does Lung Cancer Evade the Immune System?

Much has been written, including on this blog, about the rapidly expanding use of immunotherapy to treat an increasing array of cancer types, including lung cancer. The development of these new treatments, which harness a patient’s immune system to fight cancer, is built upon many years of basic research in the fields of immunology and cancer biology.

Read More

Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

NextGen Grant Recipient Harnesses the Power of Genomics to Understand Pediatric Brain Cancer

Paul Northcott, PhD, inaugural recipient of the AACR NextGen Grant for Transformative Cancer Research, has dedicated his research career to understanding a type of brain cancer called medulloblastoma, with the ultimate goal of improving treatment and prognosis for patients.

Read More